Fox Run Management L.L.C. acquired a new position in Epizyme, Inc. (NASDAQ:EPZM) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 11,700 shares of the biopharmaceutical company’s stock, valued at approximately $223,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in EPZM. Bank of New York Mellon Corp increased its holdings in shares of Epizyme by 8.2% in the first quarter. Bank of New York Mellon Corp now owns 196,837 shares of the biopharmaceutical company’s stock worth $3,377,000 after buying an additional 14,978 shares during the period. UBS Asset Management Americas Inc. purchased a new position in shares of Epizyme in the first quarter worth about $175,000. American International Group Inc. increased its holdings in shares of Epizyme by 7.1% in the first quarter. American International Group Inc. now owns 24,779 shares of the biopharmaceutical company’s stock worth $425,000 after buying an additional 1,638 shares during the period. Principal Financial Group Inc. increased its holdings in shares of Epizyme by 0.5% in the first quarter. Principal Financial Group Inc. now owns 94,173 shares of the biopharmaceutical company’s stock worth $1,615,000 after buying an additional 515 shares during the period. Finally, Teachers Advisors LLC increased its holdings in shares of Epizyme by 3.1% in the first quarter. Teachers Advisors LLC now owns 69,922 shares of the biopharmaceutical company’s stock worth $1,199,000 after buying an additional 2,093 shares during the period. Hedge funds and other institutional investors own 72.20% of the company’s stock.

Shares of Epizyme, Inc. (NASDAQ:EPZM) opened at $14.20 on Monday.

Epizyme (NASDAQ:EPZM) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.65) by $0.02. equities research analysts expect that Epizyme, Inc. will post -2.25 EPS for the current fiscal year.

In other Epizyme news, insider Peter Tai-Ching Ho sold 15,000 shares of Epizyme stock in a transaction that occurred on Tuesday, October 24th. The stock was sold at an average price of $16.44, for a total transaction of $246,600.00. Following the sale, the insider now directly owns 23,123 shares of the company’s stock, valued at approximately $380,142.12. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director David M. Mott acquired 200,000 shares of the business’s stock in a transaction on Monday, September 18th. The shares were purchased at an average cost of $15.25 per share, for a total transaction of $3,050,000.00. Following the completion of the transaction, the director now owns 6,000 shares in the company, valued at approximately $91,500. The disclosure for this purchase can be found here. Insiders sold 45,000 shares of company stock worth $733,950 over the last three months. 25.20% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: This article was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at https://theolympiareport.com/2017/11/06/11700-shares-in-epizyme-inc-epzm-acquired-by-fox-run-management-l-l-c.html.

Several research firms have recently commented on EPZM. BidaskClub downgraded Epizyme from a “hold” rating to a “sell” rating in a report on Wednesday, July 19th. Cann reiterated a “buy” rating and issued a $26.00 price objective on shares of Epizyme in a report on Tuesday, September 19th. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $26.00 price objective on shares of Epizyme in a report on Tuesday, September 19th. Leerink Swann reiterated an “outperform” rating and issued a $28.00 price objective (down previously from $31.00) on shares of Epizyme in a report on Wednesday, August 9th. Finally, Jefferies Group LLC began coverage on Epizyme in a report on Wednesday, September 20th. They issued a “buy” rating and a $23.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $22.67.

Epizyme Company Profile

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Institutional Ownership by Quarter for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.